444 related articles for article (PubMed ID: 21949767)
1. Simultaneous inhibition of mTOR-containing complex 1 (mTORC1) and MNK induces apoptosis of cutaneous T-cell lymphoma (CTCL) cells.
Marzec M; Liu X; Wysocka M; Rook AH; Odum N; Wasik MA
PLoS One; 2011; 6(9):e24849. PubMed ID: 21949767
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of mammalian target of rapamycin induces phosphatidylinositol 3-kinase-dependent and Mnk-mediated eukaryotic translation initiation factor 4E phosphorylation.
Wang X; Yue P; Chan CB; Ye K; Ueda T; Watanabe-Fukunaga R; Fukunaga R; Fu H; Khuri FR; Sun SY
Mol Cell Biol; 2007 Nov; 27(21):7405-13. PubMed ID: 17724079
[TBL] [Abstract][Full Text] [Related]
3. CGP57380 enhances efficacy of RAD001 in non-small cell lung cancer through abrogating mTOR inhibition-induced phosphorylation of eIF4E and activating mitochondrial apoptotic pathway.
Wen Q; Wang W; Luo J; Chu S; Chen L; Xu L; Zang H; Alnemah MM; Ma J; Fan S
Oncotarget; 2016 May; 7(19):27787-801. PubMed ID: 27050281
[TBL] [Abstract][Full Text] [Related]
4. Regulatory effects of a Mnk2-eIF4E feedback loop during mTORC1 targeting of human medulloblastoma cells.
Eckerdt F; Beauchamp E; Bell J; Iqbal A; Su B; Fukunaga R; Lulla RR; Goldman S; Platanias LC
Oncotarget; 2014 Sep; 5(18):8442-51. PubMed ID: 25193863
[TBL] [Abstract][Full Text] [Related]
5. Pharmacologic co-inhibition of Mnks and mTORC1 synergistically suppresses proliferation and perturbs cell cycle progression in blast crisis-chronic myeloid leukemia cells.
Teo T; Yu M; Yang Y; Gillam T; Lam F; Sykes MJ; Wang S
Cancer Lett; 2015 Feb; 357(2):612-23. PubMed ID: 25527453
[TBL] [Abstract][Full Text] [Related]
6. MNK1 pathway activity maintains protein synthesis in rapalog-treated gliomas.
Grzmil M; Huber RM; Hess D; Frank S; Hynx D; Moncayo G; Klein D; Merlo A; Hemmings BA
J Clin Invest; 2014 Feb; 124(2):742-54. PubMed ID: 24401275
[TBL] [Abstract][Full Text] [Related]
7. MNK1 inhibitor CGP57380 overcomes mTOR inhibitor-induced activation of eIF4E: the mechanism of synergic killing of human T-ALL cells.
Huang XB; Yang CM; Han QM; Ye XJ; Lei W; Qian WB
Acta Pharmacol Sin; 2018 Dec; 39(12):1894-1901. PubMed ID: 30297804
[TBL] [Abstract][Full Text] [Related]
8. Reciprocal signaling between mTORC1 and MNK2 controls cell growth and oncogenesis.
Xie J; Shen K; Jones AT; Yang J; Tee AR; Shen MH; Yu M; Irani S; Wong D; Merrett JE; Lenchine RV; De Poi S; Jensen KB; Trim PJ; Snel MF; Kamei M; Martin SK; Fitter S; Tian S; Wang X; Butler LM; Zannettino ACW; Proud CG
Cell Mol Life Sci; 2021 Jan; 78(1):249-270. PubMed ID: 32170339
[TBL] [Abstract][Full Text] [Related]
9. Eukaryotic initiation factor 4E is a novel effector of mTORC1 signaling pathway in cross talk with Mnk1.
Batool A; Majeed ST; Aashaq S; Majeed R; Bhat NN; Andrabi KI
Mol Cell Biochem; 2020 Feb; 465(1-2):13-26. PubMed ID: 31782083
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of Growth of TSC2-Null Cells by a PI3K/mTOR Inhibitor but Not by a Selective MNK1/2 Inhibitor.
Evans JF; Rue RW; Mukhitov AR; Obraztsova K; Smith CJ; Krymskaya VP
Biomolecules; 2019 Dec; 10(1):. PubMed ID: 31878201
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of Mitogen-activated Protein Kinase (MAPK)-interacting Kinase (MNK) Preferentially Affects Translation of mRNAs Containing Both a 5'-Terminal Cap and Hairpin.
Korneeva NL; Song A; Gram H; Edens MA; Rhoads RE
J Biol Chem; 2016 Feb; 291(7):3455-67. PubMed ID: 26668315
[TBL] [Abstract][Full Text] [Related]
12. The PP242 mammalian target of rapamycin (mTOR) inhibitor activates extracellular signal-regulated kinase (ERK) in multiple myeloma cells via a target of rapamycin complex 1 (TORC1)/eukaryotic translation initiation factor 4E (eIF-4E)/RAF pathway and activation is a mechanism of resistance.
Hoang B; Benavides A; Shi Y; Yang Y; Frost P; Gera J; Lichtenstein A
J Biol Chem; 2012 Jun; 287(26):21796-805. PubMed ID: 22556409
[TBL] [Abstract][Full Text] [Related]
13. MNK kinases facilitate c-myc IRES activity in rapamycin-treated multiple myeloma cells.
Shi Y; Frost P; Hoang B; Yang Y; Fukunaga R; Gera J; Lichtenstein A
Oncogene; 2013 Jan; 32(2):190-7. PubMed ID: 22370634
[TBL] [Abstract][Full Text] [Related]
14. Therapeutic inhibition of MAP kinase interacting kinase blocks eukaryotic initiation factor 4E phosphorylation and suppresses outgrowth of experimental lung metastases.
Konicek BW; Stephens JR; McNulty AM; Robichaud N; Peery RB; Dumstorf CA; Dowless MS; Iversen PW; Parsons S; Ellis KE; McCann DJ; Pelletier J; Furic L; Yingling JM; Stancato LF; Sonenberg N; Graff JR
Cancer Res; 2011 Mar; 71(5):1849-57. PubMed ID: 21233335
[TBL] [Abstract][Full Text] [Related]
15. Mitogen-activated protein kinases activate the serine/threonine kinases Mnk1 and Mnk2.
Waskiewicz AJ; Flynn A; Proud CG; Cooper JA
EMBO J; 1997 Apr; 16(8):1909-20. PubMed ID: 9155017
[TBL] [Abstract][Full Text] [Related]
16. High-dose rapamycin induces apoptosis in human cancer cells by dissociating mTOR complex 1 and suppressing phosphorylation of 4E-BP1.
Yellen P; Saqcena M; Salloum D; Feng J; Preda A; Xu L; Rodrik-Outmezguine V; Foster DA
Cell Cycle; 2011 Nov; 10(22):3948-56. PubMed ID: 22071574
[TBL] [Abstract][Full Text] [Related]
17. The androgen receptor is a negative regulator of eIF4E phosphorylation at S209: implications for the use of mTOR inhibitors in advanced prostate cancer.
D'Abronzo LS; Bose S; Crapuchettes ME; Beggs RE; Vinall RL; Tepper CG; Siddiqui S; Mudryj M; Melgoza FU; Durbin-Johnson BP; deVere White RW; Ghosh PM
Oncogene; 2017 Nov; 36(46):6359-6373. PubMed ID: 28745319
[TBL] [Abstract][Full Text] [Related]
18. Rapamycin enhances eIF4E phosphorylation by activating MAP kinase-interacting kinase 2a (Mnk2a).
Stead RL; Proud CG
FEBS Lett; 2013 Aug; 587(16):2623-8. PubMed ID: 23831578
[TBL] [Abstract][Full Text] [Related]
19. IL-2- and IL-15-induced activation of the rapamycin-sensitive mTORC1 pathway in malignant CD4+ T lymphocytes.
Marzec M; Liu X; Kasprzycka M; Witkiewicz A; Raghunath PN; El-Salem M; Robertson E; Odum N; Wasik MA
Blood; 2008 Feb; 111(4):2181-9. PubMed ID: 18025151
[TBL] [Abstract][Full Text] [Related]
20. The MNK-1/eIF4E pathway as a new therapeutic pathway to target inflammation and remodelling in asthma.
Seidel P; Sun Q; Costa L; Lardinois D; Tamm M; Roth M
Cell Signal; 2016 Oct; 28(10):1555-62. PubMed ID: 27418099
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
